用于治疗多发性硬化症的针对爱斯坦-巴尔病毒活动的许可药物的重新使用:一种系统的方法
Vivien Li1, Fiona C McKay2, David C Tscharke3
1Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3010, Australia.
CNS drugs
|January 10, 2025
概括
研究人员确定了四种药物 (famciclovir,tenofovir alafenamide,maribavir,spironolactone) 对埃普斯坦-巴尔病毒 (EBV) 有效,用于潜在的多发性硬化症 (MS) 治疗. 这些候选人对未来的MS患者临床试验充满希望.
科学领域:
- 病毒学 病毒学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 爱斯坦-巴尔病毒 (EBV) 与多发性硬化症 (MS) 的发展和活动有关.
- 持续EBV复制在MS病理中的作用仍然不清楚.
- 研究用于MS治疗的抗EBV疗法是一个关键的研究领域.
研究的目的:
- 确定现有的授权疗法具有抗EBV效果,用于MS的潜在使用.
- 评估这些疗法在MS患者的疗效,安全性和耐受性.
- 将候选人入围为后期临床试验的候选人.
主要方法:
- 从现有评论中编制了一份抗EBV疗法清单.
- 对每个候选人的临床前和临床数据进行了详细的审查.
- 使用专家小组审查 (科学和实践经验) 与验证的评分标准.
主要成果:
- 创建了11种候选药物的初始清单.
- 四种药物 - - 法姆西克洛维尔,诺福维尔,阿拉芬胺,马里巴维尔和螺旋 - - 进入了入围名单.
- 这四种药物表现出对MS有效性,安全性和耐受性的最佳平衡.
结论:
- 专家小组的审查确定了四种有前途的抗EBV治疗MS.
- 被选中的候选人显示了EBV疗效的证据和可接受的安全性.
- 这些药物适用于多发性硬化症的潜在III期临床试验.
相关概念视频
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


